Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Carlos L.  Arteaga

Carlos L. Arteaga, M.D.

Donna S. Hall Chair in Breast Cancer
Professor of Cancer Biology and Medicine (Hematology/Oncology)
Associate Director of Clinical Research
Director, VICC Breast Cancer Program
Medical Oncologist

  • Appointments
    615-322-2064
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    615-322-4967

    Office
    615-936-3524
  • Faxes
    Division of Hematology/Oncology Fax
    615-343-7602

    Clinic Fax
    615-343-9496
  • Addresses
    Clinic
    Vanderbilt Breast Center - One Hundred Oaks
    719 Thompson Lane Suite 25000
    Nashville, TN 37204

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
    Website

    Office
    Vanderbilt-Ingram Cancer Center
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
Research Specialty

Oncogene signaling in breast development/transformation and breast cancer progression Mechanisms of resistance to targeted therapies in breast cancer Novel clinical trials in breast cancer

Research Description

Carlos L. Arteaga obtained his M.D. degree with honors in 1980 at the Facultad the Ciencias M¿¿dicas of the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University (Atlanta, GA) and the University of Texas Health Sciences Center in San Antonio, TX, respectively. He joined Vanderbilt in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. Dr. Arteaga is also Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center (VICC) where he leads the Breast Cancer Program and the recently founded Center for Cancer Targeted Therapies. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action or resistance in breast cancer, and investigator-initiated clinical trials. His work includes the first demonstration that blockade of IGF-I receptor results in an antitumor effect in breast cancer; the first observation that tumor-host TGF¿¿¿-mediated interactions are critical for breast tumor establishment and metastatic progression, thus providing a basis for the targeting of TGF¿¿¿ in cancers with a therapeutic intent; one of the first observations that loss of tumor suppressor PTEN confers resistance to ERBB receptor-targeted therapies; the role of p27 haploinsufficiency in breast cancer progression; and the role of PI3K signaling on resistance to antiestrogens in breast cancer.

Since 2002, he has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE) where he co-leads several investigator-initiated clinical trials. He is funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C) and the Susan G. Komen for the Cure and Breast Cancer Research Foundations. He is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served as member of the Experimental Therapeutics-2 NIH Study Section (1998-2003), the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004-2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (2004-2007). He co-chaired the former Developmental Therapeutics Committee of ECOG and chaired the AACR Special Conferences Committee (2002-2008). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, the 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO) and the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Foundation. As of this year, he serves in the Scientific Advisory Board of the Susan G. Komen for tehe Cure Breast Cancer Foundation. He co-chaired the AACR Special Conference ¿¿¿Advances in Breast Cancer Research¿¿¿ in 2003, 2005, 2007, 2009 and 2013. He has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He is Deputy Editor of Clinical Cancer Research and member of the Editorial Board of Cancer Cell and six other peer-reviewed journals. He serves on the advisory boards of several NCI Breast Cancer Research Programs and NCI-designated Cancer Centers. In 2013, he was elected as President Elect of the American Association for Cancer Research.

Publications